[Retracted] Analysis of Efficacy, Safety, and Prognostic Factors of mFOLFOX6 Regimen Combined with Cetuximab and Simvastatin in the Treatment of K-RAS Mutant Colorectal Cancer

Table 3

Survival comparison (n (%)).

Group	First year	Third year	Fifth year
Control group (n = 58)	53.45 (31/58)	32.76 (19/58)	18.97 (11/58)
Observation group (n = 58)	72.41 (42/58)	51.72 (30/58)	37.93 (22/58)
χ^2	4.472	4.275	5.125
	0.034	0.039	0.024